AlphaRx will seek local partners with the goal of building R&D and pilot plant facilities in China. The company, which focuses on its proprietary nano drug delivery technology as a means of delivering proven therapies, plans to develop new products for infectious diseases and cancer. It also expects to develop adjuvant vaccines for influenza, such as the avian flu (H5N1) and swine flu (A/H1N1) strains. More details...

Stock Symbol: (OTCBB: ALRX)